Psilocybin as a novel treatment for chronic pain
British Journal of Pharmacology – November 29, 2024
Source: OpenAlex
Summary
Psilocybin, a potent hallucinogen, holds significant promise in medicine for chronic pain relief. Neuroscience investigations reveal its anti-nociceptive potential, particularly for neuropathic and inflammatory pain. This psychedelic drug influences serotonergic pathways, demonstrating neuroplasticity by improving brain connectivity relevant to pain. Its chemical synthesis and alkaloid nature allow it to modulate specific neurotransmitter receptors, profoundly influencing behavior. Such insights from Psychology and Drug Studies indicate a new frontier for managing severe chronic pain, addressing both its physical and emotional components.
Abstract
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain. This review primarily explores the utility of preclinical animal models in investigating the potential of psilocybin as an anti‐nociceptive agent. Initial studies involving psilocybin in animal models of neuropathic and inflammatory pain are summarised, alongside areas where further research is needed. The potential mechanisms of action, including targeting serotonergic pathways through the activation of 5‐HT 2A receptors at both spinal and central levels, as well as neuroplastic actions that improve functional connectivity in brain regions involved in chronic pain, are considered. Current clinical aspects and the translational potential of psilocybin from animal models to chronic pain patients are reviewed. Also discussed is psilocybin's profile as an ideal anti‐nociceptive agent, with a wide range of effects against chronic pain and its associated inflammatory or emotional components.